珍宝岛(603567) - 2025 Q2 - 季度财报

Important Notice This section provides important declarations from the board of directors regarding report accuracy and outlines risk statements, emphasizing forward-looking statements are not commitments Board Statement and Profit Distribution The board of directors and senior management guarantee the report's truthfulness, accuracy, and completeness, assuming legal responsibility - The board of directors and senior management guarantee the report's truthfulness, accuracy, and completeness, and assume legal responsibility[3] - This semi-annual report is unaudited, and the company's head, chief accountant, and head of accounting department declare the financial report is true, accurate, and complete[3] - There is no profit distribution plan or capital reserve to share capital conversion plan for the current reporting period[3] Risk Statement and Significant Risk Disclosures Forward-looking statements regarding future plans and development strategies in this report do not constitute actual commitments, and investors should be aware of investment risks - Forward-looking statements do not constitute actual commitments, and investors should be aware of investment risks[3] - There were no particularly significant risks materially affecting the company's production and operations during the reporting period; specific risks and countermeasures are detailed in Section III[4] Section I Definitions This section defines key terms used throughout the report, ensuring clarity and accurate understanding of the content Definitions of Common Terms This section provides definitions for common terms used in the report, including company abbreviation, controlling shareholder, GSP, GAP, "689" quality standards, IND, SRM platform, centralized procurement policies, ADC drugs, CDE, PCT pathway, MES system, B2C, and the reporting period, to ensure accurate understanding of the report's content - The reporting period refers to January 1, 2025, to June 30, 2025[12] - Key terms such as the Company, controlling shareholder, GSP, GAP, "689" quality standards, and centralized procurement policies are clearly defined[12] Section II Company Profile and Key Financial Indicators This section presents the company's basic information, stock details, and a comprehensive overview of its key accounting data and financial performance Company Basic Information This section introduces the company's Chinese name, abbreviation, foreign name and acronym, and legal representative Yan Jiujiang, along with contact information for the Board Secretary Zhang Zhongfang, and the company's registered address, office address, and website Company Basic Information | Indicator | Content | | :--- | :--- | | Chinese Name | 黑龙江珍宝岛药业股份有限公司 | | Chinese Abbreviation | 珍宝岛 | | Legal Representative | 闫久江 | | Registered Address | 黑龙江省鸡西市虎林市虎林镇红星街72号 | | Office Address | 黑龙江省哈尔滨市平房区烟台一路8号 | | Company Website | http://www.zbdzy.com | Information Disclosure and Stock Overview The company designates Shanghai Securities News, China Securities Journal, Securities Times, and Securities Daily as its information disclosure newspapers, with the semi-annual report published on www.sse.com.cn and available at the company's board office - The company's information disclosure newspapers are Shanghai Securities News, China Securities Journal, Securities Times, and Securities Daily, with the website being www.sse.com.cn[15](index=15&type=chunk) Company Stock Overview | Stock Type | Listing Exchange | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A-share | Shanghai Stock Exchange | 珍宝岛 | 603567 | Key Accounting Data and Financial Indicators During the reporting period, the company's operating revenue significantly decreased by 57.04% to 713.41 million yuan, with total profit, net profit attributable to parent company shareholders, and non-recurring net profit all turning from profit to loss, decreasing by 122.81%, 119.90%, and 123.14% respectively, while net cash flow from operating activities turned positive and increased year-on-year, primarily due to delayed national centralized procurement for traditional Chinese medicines, reduced shipments, lower product prices, decreased sales scale, and increased credit impairment losses Key Accounting Data (January-June 2025) | Indicator | Current Period (Jan-Jun) (yuan) | Prior Year Period (yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 713,410,892.19 | 1,660,604,867.40 | -57.04 | | Total Profit | -114,408,659.28 | 501,667,245.15 | -122.81 | | Net Profit Attributable to Parent Company Shareholders | -78,289,896.49 | 393,331,967.75 | -119.90 | | Net Cash Flow from Operating Activities | -62,101,205.93 | -211